SCHEMBL12878740

SCHEMBL12878740

CC(C)N1CCc2c(F)ccc(F)c2C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
GAA P10253 2/20 0.38
THRB P10828 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GRIA1 P42261 1/20 0.36
GRIA2 P42262 1/20 0.36
GRIA3 P42263 1/20 0.36
GRIA4 P48058 1/20 0.36
KCNK3 O14649 1/20 0.35
CHRNA7 P36544 1/20 0.34
KCNH2 Q12809 2/20 0.34
TMEM97 Q5BJF2 2/20 0.34
SIGMAR1 Q99720 2/20 0.34
NOTUM Q6P988 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23551264 0.88 ALDH1A1 (0.34) ALDH1A1GAATHRBL3MBTL1KMT2A
SCHEMBL25443775 0.84 HTR2C (0.39) ALDH1A1GAATHRBL3MBTL1KMT2A
SCHEMBL24316260 0.79 KCNH2 (0.48) KCNH2TMEM97SIGMAR1
SCHEMBL3440774 0.74 MAOA (0.43) KDM4ECHRNA7NOTUM
SCHEMBL16624023 0.73 ALDH1A1 (0.38) ALDH1A1GAATHRBL3MBTL1KMT2A
SCHEMBL23797859 0.73 HTR2C (0.33) GRIA1GRIA2GRIA3GRIA4KCNH2
SCHEMBL18033545 0.72 KDM4E (0.38) ALDH1A1GAATHRBL3MBTL1KDM4E
SCHEMBL25465420 0.70 PTPN2 (0.39) ALDH1A1GAATHRBL3MBTL1GRIA1
SCHEMBL17613253 0.69 HTR5A (0.35) NOTUMHTR2C
SCHEMBL24253218 0.68 KDM4E (0.36) L3MBTL1KDM4ECHRNA7NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546404-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME (US) 2013-10-01 US disclosed
US-20110038876-A1 HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS SCHERING CORPORATION 2011-02-17 US disclosed
US-20090118284-A1 Novel compounds that are ERK inhibitors MERCK SHARP & DOHME LLC 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110038876-A1 HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS MAPK1, MAPK4, MAPK10 ALDH1A1 153/4885GAA 3590/4885THRB 1693/4885
US-20090118284-A1 Novel compounds that are ERK inhibitors MAPK1, MAPK4, MAPK10 ALDH1A1 277/4885GAA 3808/4885THRB 1565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.